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Sjogren's Syndrome 
Background  
1. Definitions  
o Chronic autoimmune disorder characterized by lymphocytic destruction of 
exocrine glands 
o Frequently results in xerostomia and xerophthalmia  
2. General information  
o Underdiagnosed due to insidious onset and varied clinical presentation 
o Associated with HLA-DR 
 
Pathophysiology 
1. Pathology of disease  
o Chronic autoimmune response against epithelial cells of exocrine glands 
o B lymphocyte dysregulation / hyperactivity plays major role 
o Histological hallmark is B and T cell lymphocytic infiltration of exocrine 
glands  
2. Incidence/prevalence  
o Second most common rheumatologic disorder in the US behind fibromyalgia 
(1st) and RA (3rd)  
o Occurrence in association with another connective tissue dz: 50-60% 
o Affects 1-2 million people in US 
o Female-to-male ratio: 9:1 
o Peak incidence in 4th and 6th decades of life 
3. Risk factors  
o Female >40 yo 
o Preexisting autoimmune dz 
o Family Hx 
4. Morbidity/mortality  
o Morbidity  
 Most cases mild 
 Chronic keratoconjunctivitis 
 Corneal ulcers 
 Extraglandular dz  
 Affects 25-30% 
 Kidney, liver, lung, skin 
 Multiple dental caries, tongue fissures, oral candidiasis 
 Fatigue 
 Non-Hodgkin's lymphoma eventually develops in 2.5-5% 
 Depression, cognitive impairment 
o Mortality  
 Primary dz  
 Normal life expectancy 
 Secondary dz  
 Increased mortality from associated autoimmune disorder 
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Diagnostics 
1. History/symptoms  
o Dryness of  
 Mouth (98%)  
 Difficulty speaking, eating, swallowing 
 Eyes (93%)  
 Dryness, grittiness, pruritus, foreign body sensation 
 Required for clinical Dx 
 Skin  
 Dryness, pruritus 
 Vagina  
 Pruritus, dyspareunia 
 Nose 
 Trachea 
 Cough 
o Fatigue 
o Arthralgias (37-75%) 
o Myalgias, fibromyalgia 
o Raynaud's phenomenon (16-28%) 
o Autoimmune thyroiditis (15-33%) 
2. Physical exam  
o Keratoconjunctivitis, conjunctival injection, corneal clouding (severe Dz) 
o Decreased saliva, dry mucous membranes (with fissuring, ulceration) and 
multiple dental caries 
o Vasculitis  
 Palpable purpura, urticaria or glomerulonephritis 
o Lymphadenopathy 
o Polyneuropathy, peripheral neuropathy 
o Parotid gland enlargement, tenderness 
o Signs of other autoimmune disorders (in 2° SS: RA, SLE) 
3. Diagnostic testing  
o Majority of confirmatory tests done outside PCP office 
o Ocular evaluation  
 Schirmer test  
 Measures tear production 
 Test strip of # 41Whatman filter paper is placed in lateral third of 
lower eyelid to measure tear formation 
 Normal test: 15 mm of wet filter paper in 5 min 
 Positive test: < 5 mm in 5 min 
 Rose bengal staining  
 Identifies KCS, requires ophthalmologist  
 Instill 1% rose bengal in the eye, slit lamp exam 
 Rose bengal stains devitalized cornea / conjunctiva 
o Oral 
 Dental exam 
 Sialometry  
 Salivary flow rate measured by spitting into test for 15 minutes 
 Abnormal: unstimulated flow rate <1.5 mL/15 min 
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 Contrast sialography  
 Visualize salivary glands with injected contrast 
 Salivary scintigraphy  
 Insensitive but highly specific 
 Evaluates salivary gland function 
 Minor (lip) salivary gland biopsy  
 Can confirm SS or exclude other Dx 
o Laboratory 
 Specific (% positive in SS)  
 ANA: 55-97% 
 Anti-SS-A/Ro: 16-70% 
 Anti-SS-B/La: 7-50% 
 RF: 32-90% 
 Systemic  
 CBC, ESR, LFTs, TSH, BUN/Cr, UA 
o Other studies  
 CT scan if progression to lymphoma suspected 
4. Revised International Classification Criteria for Sjogren Syndrome  
o Dx requires presence of 4 of 6 criteria below and must include criterion #5 
or #6  
1. Ocular symptoms  
 Dry eyes >3 mths 
 Foreign body sensation in the eyes 
 Use of artificial tears >3x per day 
2. Oral symptoms  
 Dry mouth >3 mths 
 Chronic swelling of salivary glands 
 Use of liquids to facilitate swallowing 
3. Ocular signs  
 Schirmer test <5 mm/5 mins, performed without anesthesia 
 Positive vital dye staining 
4. Oral signs  
 Abnormal salivary scintigraphy 
 Abnormal parotid scintigraphy 
 Unstimulated salivary flow <1.5 mL in 15 mins 
5. Positive salivary gland biopsy  
6. Antibody screen (anti-SS-A or anti-SS-B) 
 Exclusion criteria  
 Past head and neck radiation Tx 
 Hepatitis C infection 
 AIDS 
 Pre-existing lymphoma 
 Sarcoidosis 
 Graft vs Host Dz 
 Anticholinergic drug use 
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Differential Diagnosis 
1. Dry mouth  
o Diabetes 
o Head / neck irradiation 
o Meds  
 Anti-hypertensive, anti-cholinergic, psychotherapeutic 
o Psychogenic 
2. Dry eyes  
o Chronic conjunctivitis or blepharitis, eyelid infections / abnormalities 
o Lifestyle (long driving, reading, computer use) 
o Environment (low humidity, smoke) 
o Meds  
 Anti-hypertensive, anti-cholinergic, psychotherapeutic 
o Hypovitaminosis A 
3. Parotid enlargement  
o Viral  
 Mumps, EBV, HIV, HCV, coxsackie 
o Endocrine  
 Acromegaly, hypogonadism, testosterone deficiency / hypogonadism, 
diabetes  
4. Systemic / extraglandular  
o Rheumatoid arthritis, SLE, scleroderma 
o Menopause 
o Multiple sclerosis 
o Lymphoma 
o Hepatitis 
o HIV 
o Sarcoidosis 
o Amyloidosis 
o Anxiety 
o Myopathies 
o Atopic disease 
 
Therapy 
1. Ocular dz  
o Moisture preservation and replacement methods  
 Preservative free artificial tears 
 Osmoprotective artificial tears  
 Lubricating ointments and methylcellulose inserts at night 
 Occlusion of puncta: collagen or silicone plugs (temporary), thermal / 
surgical (permanent) 
 Special goggles and glasses 
o Secretagogues: cholinergics  
 Pilocarpine 5 mg PO BID-QID 
 Cevimeline 30 mg PO TID  
 Contraindicated in asthma, angle -closure glaucoma, pregnancy 
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o Anti-inflammatory therapy  
 Topical steroids 
 Topical cyclosporine 
 Omega-3 essential fatty acids: topical or oral 
2. Oral dz  
o Saliva substitutes: lozenges, rinses, sprays, swabs 
o Frequent dental exams with fluoride treatment 
o Secretagogues  
 Pilocarpine and cevimeline as above 
o Avoid diuretics, antihypertensives, antidepressants, antihistamines 
o Oral hygiene, humidifiers, adequate water intake 
o Sugar-free gum/hard candy with xylitol: 4-5 times per day 
o Treat oral candidiasis 
3. Systemic dz  
o NSAIDs (arthralgias, myalgias, parotid pain) 
o Hydroxychloroquine 200 mg PO QD 
o Corticosteroids (severe joint Sx, vasculitis, renal dz) 
o Anxiolytics, hypnotics, antidepressants 
o Secretagogues, humidification, guaifenesin 
 
Follow-Up 
1. Referrals  
o Consider referral of patients with known or suspected Sjogren's to 
rheumatologist 
o Consider referral to ophthalmologist (eye exams) and dentist (oral exams) 
o Consider oral surgery consultation for lip biopsy 
2. Admit to hospital  
o Decision based on severity of presenting symptoms  
 
Prognosis 
1. Primary dz  
o High morbidity, increased risk of lymphoma, but not in all-cause mortality 
2. Secondary dz  
o High morbidity, increased risk of lymphoma, increased mortality 
3. Increased risk of lymphoma 
4. General  
o Usually stable exocrine function over time 
 
Prevention 
1. Early diagnosis and treatment  
o Prevent complications of dental caries, corneal ulceration, chronic oral 
infection and sialadenitis 
o Clinical surveillance for serious extraglandular / systemic complications 
o Avoid activities that cause dryness to control symptoms 
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